SCHEMBL7465807

SCHEMBL7465807

Cc1cc2nccc(N)n2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
HTT P42858 2/20 0.56
POLB P06746 3/20 0.53
NPC1 O15118 3/20 0.49
KDM4E B2RXH2 4/20 0.49
HPGD P15428 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 2/20 0.45
PKM P14618 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1A2 P05177 2/20 0.40
ALDH1A1 P00352 3/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
CYP2C19 P33261 2/20 0.38
MAPK1 P28482 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8149596 0.98 MEN1 (0.54) MEN1KMT2AHTTPOLBNPC1
SCHEMBL5066732 0.80 MEN1 (0.59) MEN1KMT2AHTTPOLBNPC1
SCHEMBL16863115 0.78 MEN1 (0.35) MEN1KMT2AHTTPOLBNPC1
SCHEMBL16866790 0.78 NOS3 (0.39) MEN1KMT2AHTTPOLBNPC1
SCHEMBL12789272 0.77 MEN1 (0.60) MEN1KMT2AHTTPOLBNPC1
SCHEMBL12789269 0.77 NPC1 (0.56) MEN1KMT2AHTTPOLBNPC1
SCHEMBL20448926 0.75 HTT (0.35) MEN1KMT2AHTTPOLBNPC1
SCHEMBL22520937 0.74 KMT2A (0.53) MEN1KMT2AHTTPOLBNPC1
SCHEMBL16116499 0.74 ALDH1A1 (0.44) MEN1KMT2AHTTPOLBNPC1
SCHEMBL12789271 0.73 HTT (0.48) MEN1KMT2AHTTPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3036231-B1 SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF JUBILANT BIOSYS LTD (IN) 2020-02-26 EP disclosed
EP-3036231-B1 SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF JUBILANT BIOSYS LTD (IN) 2020-02-26 EP disclosed
US-10273224-B2 Substituted pyrimidine compounds, compositions and medicinal applications thereof JUBILANT BIOSYS LIMITED (IN) 2019-04-30 US disclosed
US-10273224-B2 Substituted pyrimidine compounds, compositions and medicinal applications thereof JUBILANT BIOSYS LIMITED (IN) 2019-04-30 US disclosed
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-18 US disclosed
EP-3356367-A1 FUSED PYRAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-08-08 EP disclosed
US-20170002011-A1 BENZENE SULFONAMIDES AS CCR9 INHIBITORS NORGINE B.V. (NL) 2017-01-05 US disclosed
US-20170002011-A1 BENZENE SULFONAMIDES AS CCR9 INHIBITORS NORGINE B.V. (NL) 2017-01-05 US disclosed
US-20170002011-A1 BENZENE SULFONAMIDES AS CCR9 INHIBITORS NORGINE B.V. (NL) 2017-01-05 US disclosed
EP-3087074-A1 BENZENE SULFONAMIDES AS CCR9 INHIBITORS Norgine BV (NL) 2016-11-02 EP disclosed
EP-3036231-A1 SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Jubilant Biosys Ltd. (IN) 2016-06-29 EP disclosed
WO-2015097122-A1 BENZENE SULFONAMIDES AS CCR9 INHIBITORS NORGINE B.V. (NL) 2015-07-02 WO disclosed
WO-2015097122-A1 BENZENE SULFONAMIDES AS CCR9 INHIBITORS NORGINE B.V. (NL) 2015-07-02 WO disclosed
WO-2015025197-A1 SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF JUBILANT BIOSYS LIMITED (IN) 2015-02-26 WO disclosed
WO-2015025197-A1 SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF JUBILANT BIOSYS LIMITED (IN) 2015-02-26 WO disclosed
EP-0847271-B1 PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE OREAL (FR) 2002-05-02 EP disclosed
US-5856320-A ANTIBIOTIC RESISTANT STAPYLOCOCCUS KATAYAMA SEIYAKUSYO CO., LTD. (JP) 1999-01-05 US disclosed
EP-0847271-A1 PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE L'OREAL (FR) 1998-06-17 EP disclosed
WO-1997049378-A1 PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE L'OREAL (FR) 1997-12-31 WO disclosed
EP-0771803-A1 Pyrazolo(1,5-a)pyrimidinium substituted cephem derivatives, their preparation and their use as antimicrobial agents KATAYAMA SEIYAKUSYO CO. Ltd. (JP) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors PI4KA, PI4K2B, PI4KB MEN1 3280/4885KMT2A 2326/4885HTT 4824/4885
US-20170002011-A1 BENZENE SULFONAMIDES AS CCR9 INHIBITORS CCR9, CCR1, CCR4 MEN1 4883/4885KMT2A 2961/4885HTT 4683/4885
US-10273224-B2 Substituted pyrimidine compounds, compositions and medicinal applications thereof TYMP, EGFR, TK1 MEN1 4787/4885KMT2A 4738/4885HTT 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.